Recurrent Myelodysplastic Syndrome Terminated Phase 1 Trials for Lorlatinib (DB12130)

Indication	Status	Phase
DBCOND0113509 (Recurrent Myelodysplastic Syndrome)	Terminated	1

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	Treatment	Abemaciclib (DB12001) Abiraterone (DB05812) Afatinib (DB08916) Albumin human (DB00062) Avobenzone (DB09495) Bevacizumab (DB00112) Bicalutamide (DB01128) Bortezomib (DB00188) Bortezomib D-mannitol (DB16741) Cabazitaxel (DB06772) Cabozantinib (DB08875) Capecitabine (DB01101) Carboplatin (DB00958) Celecoxib (DB00482) Cobimetinib (DB05239) Copanlisib (DB12483) Dabrafenib (DB08912) Dacomitinib (DB11963) Darolutamide (DB12941) Dasatinib (DB01254) Daunorubicin (DB00694) Doxorubicin (DB00997) Durvalumab (DB11714) Enasidenib (DB13874) Entrectinib (DB11986) Enzalutamide (DB08899) Erlotinib (DB00530) Everolimus (DB01590) Fluorouracil (DB00544) Idelalisib (DB09054) Imatinib (DB00619) Ipilimumab (DB06186) Lenvatinib (DB09078) Leucovorin (DB00650) Lorlatinib (DB12130) Losartan (DB00678) Neratinib (DB11828) Nivolumab (DB09035) Octinoxate (DB09496) Olaparib (DB09074) Oxaliplatin (DB00526) Paclitaxel (DB01229) Palbociclib (DB09073) Panobinostat (DB06603) Pembrolizumab (DB09037) Pertuzumab (DB06366) Ponatinib (DB08901) Regorafenib (DB08896) Ruxolitinib (DB08877) Sirolimus (DB00877) Sorafenib (DB00398) Sunitinib (DB01268) Trametinib (DB08911) Trastuzumab emtansine (DB05773) Tretinoin (DB00755) Vemurafenib (DB08881) Venetoclax (DB11581) Vismodegib (DB08828) Vorinostat (DB02546)